Human respiratory syncytial virus (strain A2) (RSV A2)

Human respiratory syncytial virus (RSV) strain A2 is a widely utilized laboratory prototype of the RSV Subgroup A, serving as a primary model for studying viral pathogenesis and developing therapeutics [1.2.2]. As an enveloped, negative-sense, single-stranded RNA virus within the Pneumoviridae family, it primarily targets the ciliated epithelial cells of the human respiratory tract [1.4.4]. The virus is a leading cause of severe lower respiratory tract infections, including bronchiolitis and pneumonia, particularly in infants, the elderly, and immunocompromised populations [1.4.1, 1.4.2]. Its genome encodes several critical proteins that act as drug targets, most notably the fusion (F) protein, which is essential for viral entry and the characteristic formation of multinucleated syncytia [1.1.1, 1.4.1]. Current clinical interventions include monoclonal antibodies such as palivizumab and nirsevimab, which inhibit the F protein, and the broad-spectrum antiviral ribavirin [1.2.1, 1.4.4]. Research involving the A2 strain has been pivotal in identifying viral immune evasion strategies, such as the suppression of the JAK/STAT pathway by non-structural proteins, and in the ongoing development of novel fusion inhibitors and vaccines [1.3.3, 1.3.4].

Other names

RSV A2Human orthopneumovirus strain A2HRSV-A2Respiratory syncytial virus A2

Fusion inhibition, RNA-dependent RNA polymerase inhibition, Nucleocapsid protein inhibition